Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.

- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...

- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and...

- Kuria's Chief Operating Officer, Dr. Misty Stevens, to present company overview and host face-to-face booth presentation Kuria...

- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast Kuria...

- Article by Kuria's Chief Executive Officer Dr. Keith Ward summarizes role of NRF2 pathway in corneal endothelial dysfunction Kuria...

- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview Kuria...